PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q1 2023. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,413,670 | +92.8% | 1,361,460 | +39.8% | 1.66% | +100.6% |
| Q2 2023 | $14,740,516 | +224022.2% | 973,614 | +19.2% | 0.83% | +90.8% |
| Q1 2023 | $6,577 | -28.4% | 816,460 | 0.0% | 0.43% | -29.6% |
| Q4 2022 | $9,185 | -99.9% | 816,460 | -32.4% | 0.62% | -4.9% |
| Q3 2022 | $9,262,000 | -63.4% | 1,207,500 | +5.4% | 0.65% | -66.2% |
| Q2 2022 | $25,326,000 | +103.9% | 1,145,953 | +67.3% | 1.92% | +100.7% |
| Q1 2022 | $12,420,000 | +25.1% | 684,888 | -0.7% | 0.95% | +61.7% |
| Q4 2021 | $9,925,000 | -18.8% | 689,731 | 0.0% | 0.59% | +18.7% |
| Q3 2021 | $12,229,000 | -10.3% | 689,731 | -7.4% | 0.50% | +7.3% |
| Q2 2021 | $13,634,000 | -42.7% | 744,863 | -13.8% | 0.46% | -12.6% |
| Q1 2021 | $23,811,000 | – | 864,143 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $78,125,802 | 43.39% |
| venBio Partners LLC | 4,264,672 | $89,003,705 | 25.24% |
| Bain Capital Life Sciences Investors, LLC | 4,784,674 | $99,856,146 | 11.17% |
| 5AM Venture Management, LLC | 587,600 | $12,263,212 | 3.53% |
| VR Adviser, LLC | 1,563,513 | $32,630,516 | 3.44% |
| Novo Holdings A/S | 1,329,325 | $27,743,013 | 2.05% |
| Cormorant Asset Management, LP | 1,361,460 | $28,413,670 | 1.66% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $91,958,479 | 1.42% |
| Foresite Capital Management V, LLC | 33,142 | $691,674 | 1.10% |
| Soleus Capital Management, L.P. | 343,975 | $7,178,758 | 0.66% |